PD1 blockade enhances K + channel activity, Ca 2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer

• Published in: Journal for immunotherapy of cancer Vol. 8; no. 2; p. e000844
• Main Authors: Newton, Hannah S, Gawali, Vaibhavkumar S, Chimote, Ameet A, Lehn, Maria A, Palackdharry, Sarah M, Hinrichs, Benjamin H, Jandarov, Roman, Hildeman, David, Janssen, Edith M, Wise-Draper, Trisha M, Conforti, Laura
• Format: Journal Article
• Language: English
• Published: England 01-10-2020
• Subjects: Aged; Calcium - metabolism; Female; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - pathology; Humans; Immunotherapy - methods; Male; Middle Aged; Potassium - metabolism; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Signal Transduction; T-Lymphocytes, Cytotoxic - metabolism; head and neck neoplasms; programmed cell death 1 receptor; T-lymphocytes; lymphocytes; tumor-infiltrating; immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2020-000844

Immunotherapy has emerged as a promising treatment modality for head and neck squamous cell carcinoma (HNSCC). Pembrolizumab, an anti-programmed death 1 antibody, is an immunotherapy agent currently approved for metastatic HNSCC and curative intent clinical trials. Although clinical responses to pembrolizumab are promising, many patients fail to respond. However, it is well known that T cell cytotoxicity and chemotaxis are critically important in the elimination of HNSCC tumors. These functions depend on ion channel activity and downstream Ca
fluxing abilities, which are defective in patients with HNSCC. The purpose of this study was to elucidate the effects of pembrolizumab on potassium (K
) channel (KCa3.1 and Kv1.3) activity, Ca
fluxes, and chemotaxis in the cytotoxic T cells of patients with HNSCC and to determine their correlation with treatment response.
Functional studies were conducted in CD8
peripheral blood T cells (PBTs) and tumor infiltrating lymphocytes (TILs) from patients with HNSCC treated with pembrolizumab. Untreated patients with HNSCC were used as controls. The ion channel activity of CD8
T cells was measured by patch-clamp electrophysiology; single-cell Ca
fluxing abilities were measured by live microscopy. Chemotaxis experiments were conducted in a three-dimensional collagen matrix. Pembrolizumab patients were stratified as responders or non-responders based on pathological response (percent of viable tumor remaining at resection; responders: ≤80% viable tumor; non-responders: >80% viable tumor).
Pembrolizumab increased K
channel activity and Ca
fluxes in TILs independently of treatment response. However, in PBTs from responder patients there was an increased KCa3.1 activity immediately after pembrolizumab treatment that was accompanied by a characteristic increase in Kv1.3 and Ca
fluxes as compared with PBTs from non-responder patients. The effects on Kv1.3 and Ca
were prolonged and persisted after tumor resection. Chemotaxis was also improved in responder patients' PBTs. Unlike non-responders' PBTs, pembrolizumab increased their ability to chemotax in a tumor-like, adenosine-rich microenvironment immediately after treatment, and additionally they maintained an efficient chemotaxis after tumor resection.
Pembrolizumab enhanced K
channel activity, Ca
fluxes and chemotaxis of CD8
T cells in patients with HNSCC, with a unique pattern of response in responder patients that is conducive to the heightened functionality of their cytotoxic T cells.